Shares of Sanofi Consumer Healthcare India jumped 12.62% to ₹5,399.00 on Monday, following a strong set of quarterly results and successful product initiatives. The company reported a 28% year-on-year rise in revenue for Q2 at ₹220.9 crore, driven by robust export operations and the relaunch of key products.
Sales for the quarter grew 27.5% sequentially from Q1 2025 and 27.6% year-on-year from Q2 2024. Profit after tax for the quarter reached ₹60.7 crore, up 21% from the previous quarter. For the first half of FY25, product sales stood at ₹393.5 crore and net profit at ₹110.7 crore.
The company relaunched two previously recalled products — Depura 60k and Combiflam Suspension — and introduced a new offering, Allegra D, in the Allergy segment. The quarter also marked the commencement of export operations, expanding the company’s footprint internationally.
Sanofi Consumer Healthcare India became an independent legal entity on June 1, 2024, after its demerger from Sanofi India under an NCLT-approved Scheme of Arrangement.
As of 9:38 AM, the stock was trading at ₹5,399.00 with a market cap of ₹124.34 billion.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
